Policy
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
The government said the executives and the company failed to comply with its legal obligation to report thousands of suspicious orders of controlled substances to the DEA.
Plaque psoriasis is the most common type of psoriasis, caused by overproduction of skin cells. This causes inflamed, red lesions called plaques.
GenFit’s lead product candidate elafibranor snagged Breakthrough Therapy Designation from the U.S. Food and Drug Administration as a treatment for Primary Biliary Cholangitis (PBC) following strong Phase II results that demonstrated the safety and efficacy of the medication.
The rival developer appealed the recently approved 150,000 square foot development, saying it would shrink the amount of space between buildings.
Over the past few years there seems to be a growing number of people in the United States who, for a myriad of reasons, opt out of vaccinating their children against common pathogens that often have deadly effects – like the measles.
Obesity can break down our protective blood brain barrier resulting in problems with learning and memory, scientists report.
Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.
Renal cell carcinoma is also called renal cell cancer or renal cell adenocarcinoma. Approximately 90% of all kidney cancers are renal cell carcinomas.
The FDA said the approval of Teva’s product is the first generic naloxone nasal spray for use in a community setting by individuals without medical training.